SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
0.95 (USD) • At close January 8, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | SELLAS Life Sciences Group, Inc. |
Symbool | SLS |
Munteenheid | USD |
Prijs | 0.95 |
Beurswaarde | 66,891,053 |
Dividendpercentage | 0% |
52-weken bereik | 0.5 - 1.72 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Angelos M. Stergiou M.D., ScD h.c. |
Website | https://www.sellaslifesciences.com |
An error occurred while fetching data.
Over SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)